REG - Eden Research plc - Result of AGM

Eden ResearchAnnouncement

27/06/2024 15:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240627:nRSa2095Ua&default-theme=true

RNS Number : 2095U  Eden Research plc  27 June 2024

27 June 2024

 

 

Eden Research

("Eden" or "the Company")

 

Result of Annual General Meeting

 

Eden Research plc (AIM: EDEN), the AIM-quoted company focused on sustainable
biopesticides and plastic-free formulation technologies for use in the global
crop protection, animal health and consumer products industries, is pleased to
announce that all resolutions put forward to shareholders at the Company's
Annual General Meeting held earlier today were duly passed.

 

The total number of votes received by proxy on each resolution, as more fully
disclosed in the Notice of Meeting available on the Company's website, was as
follows:

 

 #  Resolution                                                     For          %      Against     %     Withheld
 1  To lay the 2023 Annual Report                                  230,082,724  93.89  14,978,000  6.11  14,818,795
 2  Re-appoint auditors                                            259,337,444  99.87  332,075     0.13  210,000
 3  Elect Derek McAllan                                            259,473,982  99.99  11,691      0.01  393,846
 4  Re-elect Sean Smith                                            259,469,698  99.94  154,821     0.06  255,000
 5  Grant authority to the Directors to allot Ordinary Shares      252,687,622  97.32  6,962,053   2.68  229,844
 6  Disapply statutory pre-emption rights on allotment of shares*  259,377,414  99.93  193,415     0.07  308,690

 

Notes:

·    * denotes Special Resolution.

·    A vote Withheld is not a vote in law and is not counted in the
calculation of the votes cast For or Against the resolution, nor in the
calculation of the percentage of issued share capital voted for any
resolution.

·    Votes For and Against are expressed as a percentage of votes validly
cast for that resolution by proxy, excluding any Withheld votes.

 

For further information contact:

 

 Eden Research plc
 Sean Smith                                                        www.edenresearch.com (http://www.edenresearch.com/)

Alex Abrey

                                                                 01285 359 555

 Cavendish Capital Markets Limited (Nominated advisor and broker)
 Giles Balleny / George Lawson (corporate finance)                 020 7220 0500

Charlie Combe (corporate broking)

Michael Johnson (sales)

 Hawthorn Advisors (Financial PR)
 Victoria Ainsworth                                                eden@hawthornadvisors.com (mailto:eden@hawthornadvisors.com)

 

Notes to Editors:

 

Eden Research is the only UK-listed company focused on biopesticides for
sustainable agriculture. It develops and supplies innovative biopesticide
products and natural microencapsulation technologies to the global crop
protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on
natural plant defence metabolites. To date, they have been primarily used on
high-value fruits and vegetables, improving crop yields and marketability,
with equal or better performance when compared with conventional pesticides.
Eden has three products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar
biofungicide which initially targets a key disease affecting grapes and other
high-value fruit and vegetable crops.  It is a useful tool in crop defence
programmes and is aligned with the requirements of integrated pest management
programmes. It is approved for sale in a number of key countries whilst Eden
and its partners pursue regulatory clearance in new territories thereby
growing Eden's addressable market globally.

 

Cedroz™( )is a bionematicide that targets free living nematodes which are
parasitic worms that affect a wide range of high-value fruit and vegetable
crops globally.  Cedroz is registered for sale on two continents and Eden's
commercial collaborator, Eastman Chemical, is pursuing registration and
commercialisation of this important new product in numerous countries
globally.

 

Eden's seed treatment product, Ecovelex was developed to safely tackle crop
destruction caused by birds - a major cause of losses in maize and other
crops. Ecovelex works by creating an unpleasant taste or odour that repels
birds, leaving the seeds safely intact and the birds unaffected and free to
find alternative food sources. The product is based on Eden's plant-derived
chemistry, registered in the EU, U.S. and elsewhere, and formulated using
Eden's Sustaine® microencapsulation system.

 

Eden's Sustaine(®)( )encapsulation technology is used to harness the
biocidal efficacy of naturally occurring chemicals produced by plants
(terpenes) and can also be used with both natural and synthetic compounds to
enhance their performance and ease-of-use. Sustaine microcapsules are
naturally-derived, plastic-free, biodegradable micro-spheres derived from
yeast. It is one of the only viable, proven and immediately registerable
solutions to the microplastics problem in formulations requiring
encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the
symbol EDEN. It was awarded the London Stock Exchange Green Economy
Mark in January 2021, which recognises London-listed companies that derive
over 50% of their total annual revenue from products and services that
contribute to the global green economy. Eden derives 100% of its total annual
revenues from sustainable products and services.

 

For more information about Eden, please visit:  www.edenresearch.com
(http://www.edenresearch.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGFRMJTMTATBMI